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Background: The increasing prevalence of obesity is considered a serious global health threat. Mainly due to
change of diet and reduced physical activity, obesity is an important risk factor for chronic diseases. A higher level
of cytokines and a general inflammatory state has also been associated with this condition. With this regard,
potential anti-obesity compounds with anti-inflammatory properties could be beneficial in better control of the
disease. p-Cymene is a natural aromatic compound that has been shown to have anti-inflammatory properties,
while the antidiabetic drug metformin has been observed to be effective as an aid for weight loss. In this study, the
effect of these comounds was compared in a high fat diet treated mice model.
Methods: 48 adult NMRI mice were randomly divided into six groups: control group receiving a normal diet, high
fat diet (HFD) fed control group, sham group receiving HFD and sunflower seed oil, Experimental group1 (E1)
receiving HFD and 20 mg/kg metformin, Experimental group2 (E2) receiving 20 mg/kg metformin and 20 mg/kg
p-cymene, Experimental group3 (E3) receiving 20 mg/kg p-cymene. Compounds were administered by intragastric
gavage for 45 days.
Results: Non-fasting glucose serum levels, ALT, and ALP of E2 and E3 decreased significantly compared to HFD
control group. In the E3 group, AST levels decrease was also significant. In E1, non-fasting glucose and TG serum
levels decreased significantly compared to HFD control group. Histological observations on liver tissue showed an
increase of lipid droplets in the HFD control group compared with the normal group, while upon treatment with
the compounds, lipid droplets decreased and the cells appeared to be more ordered.
Conclusion: p-Cymene has a potential to ameliorate biochemical parameters in high fat diet treated mice, and its
concurrent use with metformin was effective.
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The global growing prevalence of obesity is usually at-
tributed to changes in the life style of modern societies,
including the important factor of high-fat diets con-
sumption [1, 2]. The overall increase of fat intake, and
the higher energy content of fats (9 kcal per gram com-
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factors should also be taken into account [4]. Obesity
predisposes to a variety of metabolic diseases, and is re-
lated with metabolic syndrome, which is characterized
by factors such as central obesity, insulin resistance, in-
creased arterial pressure, and non-alcoholic steatohe-
patitis (NASH) [5, 6]. Moreover, metabolic syndrome
increases the risk of type 2 diabetes and cardiovascular
diseases [7]. Epidemiological studies show that nutri-
tional habits such as a high consumption of saturated fat
and cholesterol can influence the prevalence of meta-
bolic syndrome [8].le distributed under the terms of the Creative Commons Attribution License
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sponse, where abnormal adipokine production and acti-
vation of pro-inflammatory signaling pathways would
result into induction of several biological markers of in-
flammation [9]. Accordingly, a reduction in body weight
is followed by a decrease or even a normalization of
these parameters [10, 11]. Reports on animal models
support the existence of a link between inflammatory
processes and obesity, as well as it co-morbidities
[12, 13]. In addition to their role in metabolic disorders,
fat cells potential role in inflammatory process is rela-
tively recently introduced. Moreover, several findings
point to common characteristics between inflammatory
and immune cells such as complement activation and
pro-inflammatory cytokine production [14]. Similar to
macrophages, preadipocytes have the capacity for
phagocytosis and have been demonstrated to resemble
more to macrophages than adipocytes [15, 16]. These
findings are suggestive of the possibility for compounds
with anti-inflammatory properties to become potential
anti-obesity candidates.
p-Cymene (p-isopropyltoluene) is a natural aromatic
organic compound [17] used as a flavoring agent and
in the production of chemicals [18]. It is an important
component of plants belonging to the Thymus genus,
has a simple structure similar to thymol, and is the
biological precursor of carvacrol [19]. As part of vola-
tile oils extracted from plants, cymene has been
reported to have anti-bacterial and anti-oxidant prop-
erties [19, 20]. Recent studies have demonstrated in-
teresting analgesic and anti-inflammatory effect of
p-cymene itself [21–23]. With regard to these proper-
ties, we aimed at investigating the effect of cymene on
mice fed with high-fat diet, which could be considered
to be at risk of developing obesity. Cymene effect was
compared with metformin. Metformin is a safe
glucose-lowering drug which has some other indica-
tions such as treating polycystic ovarian syndrome
[24], aiding in weight loss [25], and some cases of im-
paired glucose tolerance [26].
Methods
Animals
48 adult male NMRI mice weighing approximately 20–
25 g were housed under standard laboratory conditions
with a 12 h light–dark cycle. Animals were and fed
with rodent pellets and tap water for 1 week before
starting the experiments. Animal welfare and experi-
mental procedures were carried out strictly in accord-
ance with the Guide for the Care and Use of
Laboratory Animals [27], and approval had been re-
ceived from the Islamic Azad University, Science and
Research Branch Animal Ethics Committee prior to
making the experiments.Experimental design
After accommodation for one week, mice were ran-
domly divided into six groups of eight animals as fol-
lows: (1) the normal group that received standard rodent
diet without any food restriction; (2) high fat diet control
group that received a high fat diet (HFD); (3) sham
group that received drug solvent (sunflower seed oil)
alongside with HFD; (4) Experimental group1 that re-
ceived Fat diet plus 20 mg / kg metformin; (5) Experi-
mental group 2 that received HFD plus 20 mg/kg
cymene; (6) Experimental group 3 that received HFD
with both metformin and cymen at doses of 20 mg/kg.
The experiment duration was 6 weeks and compounds
were given by oral gavage.
HFD was prepared from a mix of 15 g of mouse pellet
standard chow, 10 g of roasted ground nut, 10 g of milk
chocolate and 5 g of sesame crackers; 20 g roasted ses-
ame was added to ten-fold of these components, which
amounts into 18 kJ/g. The high fat diet treated group
was also given 240 g creamy biscuits weekly [28].Chemicals
p-Cymene (99.7 % purity) was purchased from Sigma,
USA. Metformin was from Kimi Daru Pharmaceutical
Co, Iran. Commercial kits used for determination of
blood glucose, cholesterol, triglyceride (TG), HDL-
C,LDL-C, alanine aminotransferase (ALT), and alkaline
phosphatase (ALP) were from Pars Azmoon Company,
Iran.Measured parameters
At the end of the experiment, body weights of animals
were measured; animals were anesthetized by inhalation
of mild diethyl ether, and their blood was taken. The
blood samples were allowed to clot for 30 min at room
temperature and centrifuged at 1000 × g at 37 °C for
10 min to separate the serum. Levels of non-fasting glu-
cose, cholesterol, TG, HDL-C,LDL-C and the activities
of ALT, AST and ALP were determined.Statistical analysis
Results are expressed as mean ± S.E.M. Statistical analysis
was performed using one-way ANOVA test followed by a
Tukey posthoc test. p < 0.05 was considered statistically
significant.Results
Body weight
After the end of the experiment, group 1–6 weights
were measured. As shown in Table 1, no significant dif-
ference was observed in this regard between different
groups.
Table 1 Effects of Metformin and Cymene treatment on Body Weight(g),serum non-fasting Glucose, Cholesterol (Chol), triglyceride
(TG), ALT,ALP of the mice at the week6
Control (1) High fat diet (2) Sham(3) Metformin (4) Cymene (5) Metformin + Cymene (6)
Weight(gr) 41 ±.86 40.50±.76 41.5±1.04 39.5±.1.04 40±1.15 40.071±.80
Non-fasting Glucose 273±10.4 *320±7.64 *325±11.06 ++261±4.58 +++243±7.02 +273±9.7
Chol 135±.4.5 150±.11 152±11.3 139±3.7 144±5.5 146±9
TG 120±3.6 136±.7.02 147±8.54 +96±7.63 129±8.08 110±7.02
ALT 54±3.71 67±4.04 60±3.05 53±3.06 +++43±3.05 +++38±2.51
ALP 201±5.85 220±5.29 210±7.21 200±8.54 ++172±9.165 *179±10
ALP.Data are shown as mean ± SEM. *p < 0.05 compared with the normal control group, +++p < 0.001 compared with the high fat diet group, ++p < 0.01
compared with the high fat diet group, +p < 0.05 compared with the high fat diet group
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Non-fasting Blood glucose increased significantly upon
taking HFD as well as in sham groups, compared to the
control group (p < 0.05).
Treatment with p-cymene alone, metformin alone and
metformin/cymene complex resulted in significantly de-
creased levels of blood glucose as compared with the
control group, with (p < 0.001), (p < 0.01) and (p < 0.05)
respectively (Table 1).
Lipids
Cholesterol levels of the untreated group taking HFD, as
well as the sham one were higher than the control groupFig. 1 Trichrome-stained sections of liver from control (a), HFD-given (b), m
groups. Magnification is of (400×)(although not significanltly) (Table 1). Between treated
groups, giving metformin alone had a better lowering ef-
fect on cholesterol (but not significantly). TG levels,
which were increased to some extent upon consumption
of HFD as well as in the sham group, were significantly
decreased upon metformin treatment (p < 0.05), while
other treatments, although effective, could not signifi-
cantly influence TG levels (Table 1).
ALT and ALP
Serum ALT and ALP levels of HFD-given and sham
groups were higher than those in the control group.
Upon both treatments, a significant lowering of ALTetformin-treated (c), metformin + p-Cymene (d), and p-cymene (e)
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while treatment with the cymene and metformin com-
bination made a significant difference with the normal
control group (p < 0.05). ALP levels were also signifi-
cantly affected by the combinative treatment (p < 0.05)
and cymene treatment (p < 0.01) compared with the
HFD group. Metformine alone had no significant effect
in this regard.
Histological analysis
Histological examination with trichrome staining of liver
sections from HFD-fed mice demonstrated the develop-
ment of steatosis as shown in Fig. 1. The fat droplets
were decreased in the groups that had received either
metformin or metformin combination with cymene.
Discussion
In the present study, the body weight of animals did not
change significantly upon treatment with metformin.
Typical weight loss reported upon use of metformin is
modest [29]. As an example, a weight loss of 3 kg over
16 weeks with metformin and a weight-maintaining diet
may be cited [30]. The present study period is also a
limitation in this regard. Interestingly, thymol, which is
has a similar structure to p-cymene has been reported to
decrease animals weight which had been treated with a
high-fat diet [31].
On the other hand, metformin treatment resulted into
significant decrease of blood glucose levels of HFD-
treated animals (around 20 %). Metformin is reported to
suppress glucose production in the liver and may result
to 25–30 % reduction of fasting plasma glucose concen-
trations [30, 32]. P-cymene and its combination with
metformin were also effective in this regard, a fact that
was observed with thymol too [31]. In this regard, p-
cymene could have a potentially positive effect in
diabetic state, which should be checked in suitable
diabetic models.
Lipid profile was influenced by the treatment, although
overall not significantly. The only significant effect was
obtained by the use of metformin on TG levels. Meta-
analyses have shown positive although small effect of
metformin on lipid profile factors in diabetic patients
[33], while combination of metformin with other nonin-
sulin anti-hyperglycemic drugs was found to be moder-
ate to small [34]. In NAFLD patients, as well as obese
non-diabetic patients various results had been obtained,
with effectiveness of metformin shown in some cases
[35, 36]. In other reports, thymol and carvacrol, which
have similarity with cymene in their chemical structures
have been shown to be effective on obese animals lipid
profiles [31, 35]. With regard to cymene effect, since a
decrease is observed in TG and cholesterol levels of
treated animals, the hypolipidemic potential of thecompound could not be discarded, but further testing
with other doses and treatment periods are needed.
Concerning ALT and ALP levels, HFD treated animals
showed no significant difference with the control group.
Metformin supplementation had also no significant ef-
fect on these levels, where cymene caused a significant
decrease of ALT and ALP. In reported studies, metfor-
min (1–1.5 g/day) has been effective in reduction of
ALT levels [37, 38]. The lack of metformin effect ob-
served in this study may be related to the limited period
of the study.
Conclusions
Use of the simple compound p-cymene has shown a sig-
nificant effect on blood glucose levels of HFD-treated
animals, as well as on ALT and ALP levels. Slight effects
were also detected toward lipid profiles which may be
indicative of a potential of this compound in this regard.
Overall, the effects of cymene were comparable with met-
formin, and show its potential as an alternative to the lat-
ter. Further studies involving longer periods are needed to
fully validate these results.
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